Literature DB >> 26443279

Response evaluation in mesothelioma: Beyond RECIST.

Lin Cheng1, Nina Tunariu2, David J Collins1, Matthew D Blackledge1, Angela M Riddell3, Martin O Leach1, Sanjay Popat4, Dow-Mu Koh5.   

Abstract

Malignant pleural mesothelioma (MPM) typically demonstrates a non-spherical growth pattern, so it is often difficult to accurately categorize change in tumour burden using size-based tumour response criteria (e.g., WHO (World Health Organisation), RECIST (Response Evaluation Criteria in Solid Tumours) and modified RECIST). Functional imaging techniques are applied to derive quantitative measurements of tumours, which reflect particular aspects of the tumour pathophysiology. By quantifying how these measurements change with treatment, it is possible to observe treatment effects. In this review, we survey the existing roles of CT and MRI for the management of MPM, including the currently applied size measurement criteria for the assessment of treatment response. New functional imaging techniques, such as positron emission tomography (PET), diffusion-weighted MRI (DWI) and dynamic contrast-enhanced MRI (DCE-MRI) that may potentially improve the assessment of treatment response will be highlighted and discussed.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  CT; DCE-MRI; DWI; Mesothelioma; PET; Treatment response evaluation

Mesh:

Year:  2015        PMID: 26443279     DOI: 10.1016/j.lungcan.2015.08.012

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  12 in total

1.  The Role of 18F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Predicting Pathologic Response After Induction Therapy for Thymic Epithelial Tumors.

Authors:  Koichi Fukumoto; Takayuki Fukui; Toshiki Okasaka; Koji Kawaguchi; Shota Nakamura; Shuhei Hakiri; Naoki Ozeki; Tomoshi Sugiyama; Katsuhiko Kato; Kohei Yokoi
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

Review 2.  Malignant pleural mesothelioma: predictors and staging.

Authors:  William G Richards
Journal:  Ann Transl Med       Date:  2017-06

Review 3.  Clinical diagnosis of malignant pleural mesothelioma.

Authors:  Andrea Bianco; Tullio Valente; Maria Luisa De Rimini; Giacomo Sica; Alfonso Fiorelli
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

4.  Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.

Authors:  Feng Li; Mehwish Ahmad; Fawwaz Qayyum; Christopher M Straus; Heber MacMahon; Hedy Kindler; Samuel G Armato
Journal:  Eur Radiol       Date:  2019-01-07       Impact factor: 5.315

Review 5.  Novel insights into mesothelioma biology and implications for therapy.

Authors:  Timothy A Yap; Joachim G Aerts; Sanjay Popat; Dean A Fennell
Journal:  Nat Rev Cancer       Date:  2017-07-25       Impact factor: 60.716

6.  Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations.

Authors:  Sebastian Curcean; Lin Cheng; Simona Picchia; Nina Tunariu; David Collins; Matthew Blackledge; Sanjay Popat; Mary O'Brien; Anna Minchom; Martin O Leach; Dow-Mu Koh
Journal:  JTO Clin Res Rep       Date:  2021-11-02

Review 7.  Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-05-24       Impact factor: 2.374

Review 8.  Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group.

Authors:  Samuel G Armato; Kevin G Blyth; Jane J Keating; Sharyn Katz; Selina Tsim; Johan Coolen; Eyjolfur Gudmundsson; Isabelle Opitz; Anna K Nowak
Journal:  Lung Cancer       Date:  2016-09-05       Impact factor: 5.705

9.  Diffusion-weighted magnetic resonance imaging is useful for the response evaluation of chemotherapy and/or radiotherapy to recurrent lesions of lung cancer.

Authors:  Katsuo Usuda; Shun Iwai; Aika Funasaki; Atsushi Sekimura; Nozomu Motono; Munetaka Matoba; Mariko Doai; Sohsuke Yamada; Yoshimichi Ueda; Hidetaka Uramoto
Journal:  Transl Oncol       Date:  2019-03-09       Impact factor: 4.243

10.  Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria.

Authors:  Martina Vivoda Tomšič; Sotirios Bisdas; Viljem Kovač; Igor Serša; Katarina Šurlan Popovič
Journal:  Cancer Imaging       Date:  2019-02-27       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.